This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Rapamycin
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
==Structure== | ==Structure== | ||
| - | <StructureSection load='' size='340' side='right' caption='' scene='82/821566/Rapamycin/ | + | <StructureSection load='' size='340' side='right' caption='' scene='82/821566/Rapamycin/3'> |
[[Image:Rapamycin.png]] | [[Image:Rapamycin.png]] | ||
| - | Rapamycin, a macrolide, has a <scene name='82/821566/Rapamycin/ | + | Rapamycin, a macrolide, has a <scene name='82/821566/Rapamycin/3'>cyclic structure</scene>. It <scene name='82/821566/Rapamycin/2'>binds to the regulator protein mTORC1</scene> with the help of another protein called FKBP52<ref>PMID: 23358420</ref> |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Current revision
Rapamycin, isolated from the bacterium Streptomyces hygroscopicus, is an immuno-suppressant and anticancer drug[1]. It acts by binding the the mTORC1 protein complex, a kinase that regulates cell growth and metabolism. In the future, it might also be used in treatment of type 2 diabetes[2].
Structure
| |||||||||||
References
- ↑ https://en.wikipedia.org/wiki/Sirolimus
- ↑ https://doi.org/10.3389/fphar.2016.00395
- ↑ Marz AM, Fabian AK, Kozany C, Bracher A, Hausch F. Large FK506-binding Proteins Shape the Pharmacology of Rapamycin. Mol Cell Biol. 2013 Jan 28. PMID:23358420 doi:http://dx.doi.org/10.1128/MCB.00678-12
